Journal of the Neurological Sciences
Volume 298, Issue 1 , Pages 21-22 , 15 November 2010

How do we get better at identifying patients with atrial fibrillation who are at ‘truly low risk’ or ‘truly high risk’ of stroke?

Received 29 July 2010 ,Revised 6 August 2010 ,Accepted 6 August 2010.

References 

  1. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99(2):295–304
  2. Stroke in AF Working Group . Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554
  3. Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost. 2008 Jul;100(1):11–13
  4. Apostolakis S, Shantsila E, Lip GY, Lane DA. Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”. Thromb Haemost. 2009 Nov;102(5):914–915
  5. Healey JS. Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”. Thromb Haemost. 2009 Nov;102(5):912–913
  6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867
  7. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, et al. Euro Heart Survey Investigators. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153:1006–1012
  8. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645e4
  9. Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J, et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace. 2010;12:779–784
  10. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39:1482–1486
  11. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost. 2010;103:833–840
  12. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901–1910
  13. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK. ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810–815
  14. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009;101:367–372
  15. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation — friend or foe?. Thromb Haemost. 2010;104(1):45–48
  16. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272
  17. Kim YD, Park B, Cha MJ, Nam CM, Nam HS, Ha JW, et al. Stroke severity in concomitant cardiac sources of embolism in patients with atrial fibrillation. J Neurol Sci. 2010;298:23–27
  18. Wysokinski WE, Ammash N, Sobande F, Kalsi H, Hodge D, McBane RD. Predicting left atrial thrombi in atrial fibrillation. Am Heart J. 2010;159:665–671
  19. Puwanant S, Varr BC, Shrestha K, Hussain SK, Tang WH, Gabriel RS, et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol. 2009;54:2032–2039
  20. Rietbrock S, Plumb JM, Gallagher AM, van Staa TP. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost. 2009;101(3):527–534
  21. Mant JW. Pro: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation’. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb Haemost. 2008;100(1):14–15

PII: S0022-510X(10)00364-3

doi: 10.1016/j.jns.2010.08.015

Journal of the Neurological Sciences
Volume 298, Issue 1 , Pages 21-22 , 15 November 2010

Article Tools